45 results on '"Peters, Finn"'
Search Results
2. Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function
3. The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration
4. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
5. Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
6. Seeding and transgenic overexpression of alpha‐synuclein triggers dendritic spine pathology in the neocortex
7. Benefits of global mutant huntingtin lowering diminish over time in a Huntington’s disease mouse model
8. β-secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice
9. Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model
10. Intraneuronal APP and extracellular Aβ independently cause dendritic spine pathology in transgenic mouse models of Alzheimer’s disease
11. Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition
12. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease
13. A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s disease
14. Pre-therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic Immunomodulation
15. Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition
16. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition
17. Author response: Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition
18. Microbiota-derived short chain fatty acids promote Aβ plaque deposition
19. Tau deletion reduces plaque‐associated BACE 1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease
20. Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation.
21. Early and longitudinal microglial activation but not amyloid accumulation predict cognitive outcome in PS2APP mice
22. MOESM1 of The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration
23. Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology
24. Pharmacological BACE1 inhibitor treatment during early progression of β-amyloid pathology maximizes therapeutic efficacy
25. Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid-β Mouse Model
26. In vivoimaging reveals reduced activity of neuronal circuits in a mouse tauopathy model
27. Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo μPET-study
28. Comparison of F-18-T807 and F-18-THK5117 PET in a Mouse Mode of Tau Pathology
29. Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second Generation Amyloid-beta Mouse Model.
30. Early and Longitudinal Microglial Activation but Not Amyloid Accumulation Predicts Cognitive Outcome in PS2APP Mice
31. Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology
32. Time Courses of Cortical Glucose Metabolism and Microglial Activity Across the Life Span of Wild-Type Mice: A PET Study
33. In vivo imaging of presynaptic pathology in a mouse model of Alzheimer's disease
34. In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model.
35. Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology.
36. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
37. Obesity, energy intake and physical activity in rural and urban New Zealand children
38. Tau deletion reduces plaque‐associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
39. Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
40. Additional file 1: of Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimerâ s disease tau
41. Additional file 1: of Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimerâ s disease tau
42. β-secretase inhibition prevents structural spine plasticity deficits in App NL-G-F mice.
43. Early and Longitudinal Microglial Activation but Not Amyloid Accumulation Predicts Cognitive Outcome in PS2APP Mice.
44. In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model.
45. Comparison of 18 F-T807 and 18 F-THK5117 PET in a Mouse Model of Tau Pathology.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.